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Abstract
Therapeutic strategies are being clinically tested either to eradicate the latent HIV reservoir or to 
achieve virologic control in the absence of antiretroviral therapy (ART). Attaining this goal will 
require a consensus on how best to measure the levels of persistently-infected cells with the 
potential to cause viral rebound upon ART cessation to assess the results of cure-directed 
strategies in vivo. Current measurements assess different aspects of the HIV provirus and its 
functionality, and produce divergent results. Here, we provide the collective insight and position 
from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements to prioritize in 
HIV cure-directed clinical trials.
Keywords
HIV latency; HIV reservoirs; Viral measurements; HIV Cure; HIV persistence; Replication-
competent HIV
Antiretroviral therapy (ART) has dramatically reduced morbidity and mortality for people 
living with HIV (PWH) by effectively suppressing viral replication to undetectable levels in 
plasma.1–4 However, ART requires lifelong administration and does not eradicate HIV, 
which continues to cause immune activation, chronic inflammation, and ongoing damage to 
multiple organs systems.5–8 Therefore, effective therapeutic strategies are needed to cure 
HIV infection.
The main obstacle to cure HIV is that the virus establishes stable reservoirs of persistently-
infected cells, in blood and different anatomical sites.9 These reservoirs persist despite long-
term ART and can be broadly divided into two groups. The “latent reservoir” in which cells 
carry an integrated copy of the viral genome that does not express viral transcripts or 
proteins. These latent proviruses are not affected by ART or cleared by the immune system; 
however, they can revert to a viral productive state upon stimulation.10–12 In addition to the 
latent reservoir, the active reservoir is a minor population of transcriptionally-active cells, 
producing HIV RNA/proteins and possibly virions, that can be detected in PWH despite 
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long-term ART. Targeting and eliminating both types of reservoirs is the focus of the quest 
for an HIV cure.13
Currently, several clinical trials are being conducted to evaluate the impact of potential 
therapeutic strategies to cure HIV. The success of these trials hinges on the ability to 
measure the size of HIV reservoirs before and after such interventions as a guide to ART 
interruption. However, there is no consensus on how to use the variety of assays currently 
available to evaluate the size of HIV reservoirs with the potential to cause viral rebound in 
the absence of ART. In this Perspective, we provide our collective view on which viral 
measurements to prioritize in HIV cure-directed clinical trials (Figure 1).
Challenges to measuring the HIV reservoir
There are four major challenges facing clinical trial design when measuring changes in HIV 
reservoir size on ART: the vast majority of proviruses persisting in ART-treated PWH harbor 
mutations and/or deletions rendering them defective and unable to replicate; not all intact 
genomes (genomes with no defective mutations/deletions) are inducible to produce virions; 
the frequency of latently-infected cells is very low; and the vast majority of HIV reservoirs 
are in tissues that cannot be accurately sampled with current specimen collection 
approaches.14–20
HIV cure-directed studies in ART-suppressed PWH currently measure levels of total proviral 
DNA, intact provirus, transcriptionally-competent provirus (viral RNA), translationally-
competent provirus (protein), and replication-competent virus. These clinical studies 
primarily measure changes in the aforementioned viral measures using four specimen types: 
peripheral blood mononuclear cells (PBMCs) obtained either by phlebotomy or 
leukapheresis, and biopsies from gut-associated lymphoid tissue (GALT) or lymph nodes 
(LN). It’s probable that no measurement of a single compartment can fully inform on the 
totality of reservoir dynamics under ART. Most clinical trial designs mainly collect 
peripheral blood for the ease of longitudinal sampling, the willingness of participants to 
donate blood frequently, its low cost, high throughput, and ease of collection at clinical sites 
around the world. As mentioned, GALT and LN biopsies are also collected in some clinical 
trials. While, HIV might persist in other tissues, the collection of these other tissues is 
challenging.
Measuring levels of replication-competent virus or intact HIV genomes
Quantitative viral outgrowth assay (QVOA) and its derivates
Until recently, the QVOA and its derivatives (see Table 1) were the standard measurements 
of the replication-competent HIV reservoir.21,22 However, we think that QVOA is not well 
suited for cure-directed studies due to its high cost, labor requirements, need for a high 
number of cells (limiting its use to peripheral blood cells), and biosafety containment 
requirements. Moreover, QVOA underestimates the size of the replication-competent viral 
reservoir, as not all intact HIV proviruses can be induced to release virus following a single 
round of T cell activation.20,23
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Other assays have been developed based on QVOA, such as Q2VOA. Q2VOA has the same 
limitations of QVOA in under-estimating reservoir size; however, it provides added 
sequence information in addition to an estimate of reservoir size.24 Independently from 
QVOA or other similar outgrowth-based assays, single-genome, near full-length proviral 
sequencing does allow for a detailed analysis of the proviral landscape such as an ability to 
identify the frequency of intact and defective proviral species, phylogenetic sequence 
analysis and detection of clonal intact proviral sequences.19,20,25,26 However, near full-
length proviral sequencing is laborious and time-intensive, rendering it unfeasible for large 
HIV cure-directed clinical trials. In addition, methods relying on long-distance PCR may not 
be highly quantitative due to the possible inefficiency of such reactions.
Emerging PCR-based techniques to measure intact HIV DNA levels
The above limitations prompted the development of more sensitive and straightforward 
assays to distinguish between intact and defective proviruses. New assays, including the 
intact proviral DNA assay (IPDA),27 and the Quadruplex qPCR (Q4PCR) assay,28 now offer 
promising strategies that require a relatively small number of cells to estimate the size of 
genetically-intact HIV populations in a labor and cost-effective manner, when compared to 
QVOA or near full-length HIV provirus genome sequencing. Based on the specific 
requirements of these two assays, we think that IPDA is best suited for high-throughput 
analysis of large interventional or observational clinical studies; for instance, a recent 
longitudinal cohort analysis evaluated the decay rate of intact and defective proviruses in a 
large cohort of patients using IPDA.29 However, these studies have also revealed that <2% of 
estimated intact proviruses are expected to be induced ex vivo. This observation raises the 
question whether we would also need to add an inducibility index to IPDA measures as 
defined by a concurrent viral outgrowth assays (discussed below) to define the relative 
frequency of cells producing replication-competent virus.30 On the other hand, the Q4PCR 
assay interrogates four regions of the genome after a near-full-length PCR, providing more 
detailed information on proviral integrity and direct confirmation of viral sequences. These 
added steps in Q4PCR may provide valuable information in smaller trials or trial designs 
where viral sequencing is important, but near full-length sequencing is prohibitively costly 
or time-consuming. For example, HIV cure-directed studies that use a lentiviral vector as a 
delivery mechanism such as the CD4 CAR (NCT03617198) may best be served by the 
Q4PCR assay to distinguish between circulating HIV and lentiviral vector sequences.
While these two newer assays are promising, future studies are needed to: validate them in 
large independent cohorts; perform blinded comparisons between laboratories; assess 
relationship with induction potential; and establish if levels of intact proviral HIV DNA in 
the blood and/or tissues correlate with time to or magnitude of viral rebound during an 
analytical treatment interruption (ATI). As with any sequence-based assay, sequence 
polymorphisms preclude amplification in a fraction of PWH and may require alternative 
primer/probe sets. It will be critical to validate the ability of the primer/probe sets used in 
these assays to overcome the intra- and inter-individual diversity in HIV sequences. This 
also includes validating these assays among different HIV clades as most studies to date 
have been performed in regions with dominant clade B. Importantly, these assays can be 
performed on frozen cells; therefore, we suggest storing of samples from clinical trials until 
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adequate validation of these assays is completed. With regards to the future use of these 
assays using GALT biopsies, we currently recommend the analysis of ileum tissue due to 
higher lymphocyte-rich regions, and the pre-enrichment of CD45+ leukocytes as it has been 
shown that this step increases the sensitivity of detecting persistent HIV measures.31,32
The murine viral outgrowth assay (mVOA)
mVOA, in which large numbers of cells from PWH can be adoptively transferred to NSG 
[immunodeficient non-obese diabetic (NOD)] mice and monitored for viremia, represents 
another tool to assess levels of replication-competent HIV proviruses.33,34 This assay may 
be more sensitive than traditional ex vivo outgrowth assays in detecting replication-
competent HIV from PWH with very low to undetectable levels of HIV DNA and RNA in 
peripheral blood mononuclear cell (PBMC), due to the in vivo setting.33,34 This assay, by 
testing a large number of cells in an in vivo environment that may support amplification over 
time, maybe useful for confirming the absence of replication-competent cells when (1) no 
other assays detect infectious virus or intact provirus, and (2) no ATI is included in the trial 
design. However, it is important to note that this assay is laborious, costly, and time-
consuming.
HIV integration sites analysis
It is also possible to measure the distribution of HIV DNA integration sites in PWH samples, 
which can provide information on reservoir structure and maintenance. Quantitative 
understanding of HIV integration sites can identify HIV-infected cells which are 
preferentially proliferated in vivo. Understanding why certain HIV-infected cells 
preferentially proliferate in vivo can provide important information for prioritizing the 
elimination strategies targeting the proliferating HIV latent reservoir, a current major 
challenge in the HIV cure field. Second, integration site data may also be linked to studies of 
provirus inducibility.35,36 For example, HIV is known to favor integration in active 
transcription units, and associated features,37,38 and this may influence subsequent proviral 
gene activity.39,40 Finding ways to target proviruses that are not readily induced may be key 
to reaching ART-free viral control (functional cure). An integrative understanding of HIV 
integration site and proviral genome integrity (by using MIP-seq39 or MDA-SGS41) or HIV 
integration site and HIV-driven aberrant cancer gene expression (by using HIV SortSeq42) 
may provide new therapeutic insights into targeting intact and inducible HIV reservoirs. This 
level of analysis requires a large number of cells (i.e., leukapheresis) and a high investment 
(labor and cost) per study participant analyzed.
The BEAT-HIV Collaboratory position on assays measuring the amount of putative intact 
HIV proviral genomes is to give priority to either the IPDA or Q4PCR approach using both 
blood and tissue samples (pending validation; Figure 1) when assessing the success of a 
potential curative strategy in targeting the levels of intact HIV DNA. When cell numbers 
allow and undetectable levels of HIV are noted in trial designs that do not include a 
treatment interruption phase to assess viral rebound after ART interruption, the inclusion of 
mVOA (for understanding inducible reservoirs) and MIP-Seq (for more in-depth qualitative 
insights on viral sequences) on a limited subgroup of clinical trial participants should be 
considered.
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Measuring levels of translationally-competent virus
Studying cellular reservoirs capable of producing HIV antigen, e.g., gag p24 protein, is 
biologically and scientifically relevant as protein is more likely, compared to RNA 
transcripts, to trigger innate and adaptive immune responses, lead to persistent immune 
activation, and play a role in HIV pathogenesis. HIV antigen is also the target of several 
immune-based curative strategies.43,44 Furthermore, since viral protein production requires 
intact viral reading frames, viral protein detection would be expected to identify inducible 
proviruses relatively frequently, albeit not always as defective proviruses can also express 
viral proteins.20,45,46 Thus, evaluating the translational competency of HIV reservoirs (latent 
or active) complements measures of genetically intact, replication-competent virus.
Digital p24 Single Molecule Assay Technology (SIMOA) immunoassay
Current protein-based measurements take advantage of the natural amplification provided by 
the high number of HIV gag molecules generated per cell or per virion, together with 
emerging ultra-sensitive methods for protein detection. The enhanced digital p24 SIMOA 
immunoassay provides rapid and direct quantification of viral antigen from single HIV+ cell 
in the absence or presence of CD4+ T cell stimulation (i.e., steady-state or inducible 
reservoirs, respectively).43,47–50 Advantages of this assay include measurement of virus with 
sufficient genetic integrity to drive transcription, translation, and downstream processing, 
however, this approach will likely overestimate the size of the replication-competent 
reservoir as the increased sensitivity of this assay may allow detection of virion production 
by cells harboring replication-defective proviruses (e.g., a provirus with packaging signal 
deletions).20,46 In all outgrowth assays, a failure to document exponential increases in viral 
RNA or protein over time in culture may contribute to an over-estimation of reservoirs if 
only measured by ultra-sensitive p24 SIMOA.51–53
Induced cell-associated p24 quantification may also inform on the relationships between 
HIV persistence and immunological responses as translational-competent cells may 
contribute to chronic inflammation and immune activation during ART. Lastly, the digital 
p24 SIMOA assay requires a small number of cells and is applicable to a variety of 
specimens from various anatomical compartments (blood or tissue). Therefore, our 
collective recommendation is to include the induced p24 expression as measured by the 
SIMOA immunoassay (Induced p24/SIMOA) as one of the primary readouts for quantifying 
levels of steady-state/inducible translationally-competent virus in blood and/or tissues 
during HIV cure-directed clinical trials (Figure 1).
Single-cell FISH-flow cytometry and other assays measure translationally-competent virus
Apart from the induced p24/SIMOA assay, assessments of induced p24 expression can also 
be performed using live cells by single-cell FISH-flow cytometry allowing for the added 
assessment of the frequency of infected cells.54–56 Other assays of the translationally-
competent virus, such as ultrasensitive QVOA p24 SIMOA (measuring p24) or QVOA 
cfRNA (measuring cell-free HIV RNA; a surrogate of HIV virions produced upon ex vivo 
stimulation of resting CD4+ T cells) have been developed using a limiting dilution step of 
input cells.57–59 Compared to the QVOA, flow cytometry-based assays are simpler, have 
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higher throughput and sensitivity, and require few cells. However, in contrast to the QVOA, 
they measure the frequency of cells that are inducible ex vivo to produce viral virions and/or 
HIV protein [whether harboring defective or replication-competent (intact) virus]. Further 
studies are needed to evaluate whether the measurements from any of these assays 
measuring the levels of translationally-competent provirus can reflect the dynamics of an 
ATI viral rebound in vivo.
The BEAT-HIV Collaboratory position on assays measuring the amount of translationally-
competent virus is to give priority to direct p24 immunoassay quantification (either without 
stimulation or following short ex vivo stimulation to reactivate virus without expansion) 
followed by measuring changes in inducible infected cell frequency by QVOA cfRNA or 
QVOA p24 SIMOA (measuring frequency of cells producing virions or viral proteins 
followed ex vivo stimulation and expansion) (Figure 1). It is important to note that it remains 
undetermined how different stimuli or repeated stimulations may affect the reactivation 
potential of different infected cells to express p24, therefore, stimuli used and limitations of 
each assay should be carefully considered.60
Measuring levels of transcriptionally-competent virus
Viral RNA assays have been used broadly to measure both productive infection and latency 
reversal; however, given that >90% of proviral DNA is defective, these measures 
overestimate the size of the reservoir capable of producing infectious virions and are 
inadequate for determining the effectiveness of interventions targeting translationally- or 
replication-competent reservoirs.19,20,27 In contrast, measuring cell-associated HIV RNA 
transcripts that persist during ART (total, elongated, unspliced, polyadenylated, and multi-
spliced) or the ratio of HIV RNA to HIV DNA might indicate the degree of HIV residual 
transcriptional activity.59,61–63 These measures could provide an early indication of change 
following therapeutic interventions that aim to either stimulate or block viral transcription. 
Such assays provide 1–2 log10 greater sensitivity over assays of intact or replication-
competent virus by providing a greater dynamic range to measure the impact of an effective 
intervention. Moreover, transcriptionally-competent HIV infected cells may be a significant 
contributor to chronic inflammation and immune activation during ART, which could impact 
the efficacy of curative strategies. Importantly, levels of cell-associated HIV RNA during 
ART (both unspliced and multi-spliced) can serve as predictors of viral rebound after 
therapy interruption,64,65 supporting the biological and clinical relevance of these HIV RNA 
measures in measuring the size of HIV reservoirs.
TILDA and HIV-RNAscope
It should be noted that qPCR and droplet digital PCR assays measuring levels of HIV 
transcripts without a serial dilution step of input cells only evaluate the levels of HIV RNA 
in bulk cells, but do not determine the frequency of cells that are transcriptionally-
competent. Characterizing the frequency of transcriptionally-competent cells before and 
after interventions can be an important parameter, especially in the context of clinical 
interventions expected to eliminate cells that are HIV transcriptionally active. If HIV RNA+ 
cell frequency is needed, we suggest the inclusion qPCR and droplet digital PCR assays 
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measuring levels of HIV transcripts with a serial dilution step of input cells, such as the 
Tat/Rev Induced Limiting Dilution Assay (TILDA) 66 or similar assays 59 (Figure 1). In 
addition, measuring levels of residual viremia may be useful when evaluating strategies 
aimed to reactivate the latent reservoir (shock and kill strategies). However, in the absence of 
a reactivation strategy, the dynamic range of assays measuring residual plasma HIV RNA 
after ART limits the use of this assay in cure-directed study design67–69. Finally, for tissue-
based specimens, direct in situ hybridization-based assays, such as HIV-DNAscope and 
HIV-RNAscope, have high priority, as isolation of substantial numbers of CD4+ T cells and 
macrophages from biopsies may be difficult. These assays provide an important spatial 
context of HIV reservoirs as well as an understanding of the microenvironments/cellular 
immune neighborhoods in which HIV RNA+ and DNA+ reservoirs reside within tissue (i.e., 
providing a superior understanding of the cellular distribution, the phenotype and 
transcriptional state of persistently infected cells in vivo).53,70,71 However, the ability of 
these assays to quantify total tissue reservoirs is unknown and unlikely considering the 
limited tissue sampling available from participants in a clinical trial.
The BEAT-HIV Collaboratory position on assays measuring the amount of transcriptionally-
competent virus is to give priority to the use of RNA (and DNA)-scope (when using tissue 
specimens) assays to be followed by levels of HIV transcripts and the frequency of HIV 
transcriptionally competent cells, particularly if the strategy is expected to stimulate or block 
HIV transcription.
Measuring total and integrated levels of HIV DNA
Reservoir size has been characterized by PCR quantification of the total, integrated, and 
episomal HIV DNA. Interpretation of these measures is complicated by the differential 
decay rates of HIV DNA and the fact that the vast majority of proviral DNA is profoundly 
defective.19,20,27 Despite this limitation, total HIV DNA has been measured in many settings 
and provided important insights on HIV persistence.53,72–76 In addition, measuring total 
HIV DNA levels could be the only assay possible when a limited cell number is available as 
other assays might not be sensitive enough for quantitative measurement. In addition to 
levels of total HIV DNA, specific assays have been developed to measure integrated HIV 
DNA and episomal HIV DNA (2-LTR circles). Since post-integration latency is thought to 
represent the major form of viral persistence, levels of integrated HIV DNA provide a more 
accurate measure of HIV reservoir size than total HIV DNA and in steady-state conditions 
are correlated with IPDA measures.77 Integrated HIV DNA assays require either a pre-PCR 
separation of high molecular weight DNA78 or a pre-amplification step with primers for 
genomic Alu elements and HIV sequences.72,79–81 In summary, based on the goal of cure-
directed studies to detect a change in replication-competent provirus and availability of 
assays such as IPDA or Q4PCR that are able to estimate a change in putative intact HIV 
provirus numbers irrespective of total HIV DNA with predominant defective proviruses, it is 
our collective view to place a lower priority for measuring levels of integrated HIV DNA in 
clinical trials unless available cell number is limited (Figure 1).
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HIV latency has been extensively characterized in resting CD4+ T cells, which typically do 
not produce virions or viral antigens ex vivo before activation by a latency-reversing agent.12 
HIV can also be detected in cells expressing classical activation markers such as HLA-DR.
12,53,82 However, the extent to which a steady-state of activated infected CD4+ T cells 
contribute to HIV persistence during ART remains unknown as these cells are expected to 
have a short half-life by expressing viral antigens exposing these cells to viral cytopathic 
effects and/or immune clearance. HIV has also been detected in different memory cell 
subsets.83 It is important to note that recent studies show that the markers used to define 
memory cell populations change with activation state and that intact proviruses are found in 
most if not all T cell subsets.30,56,83 For example, naïve CD4+ T cells can harbor a small but 
significant portion of HIV replication-competent virus in vivo.84 Given the absence of a 
single marker that can identify latently infected CD4+ T cells, and the wide distribution of 
the reservoir between T cell subsets, we suggest performing the aforementioned measures 
first on total CD4+ T cells. Analysis of total CD4+ T cells would more accurately reflect the 
steady-state of HIV persistence, with the caveat that virus detected may originate from both 
latently-infected cells and recently activated CD4+ T cells (latent and active reservoirs). 
When larger quantities of CD4+ T cell are available, as in the case of leukapheresis or lymph 
node biopsy, measurements can be performed on different CD4+ T cell subsets,83 including 
resting, naïve, central memory, effector memory, follicular helper CD4+ T cells, resident 
memory CD4+ T cells, regulatory T cells, and other relevant cell populations.
Finally, we acknowledge that CD4+ T cells may not constitute the sole viral reservoir in vivo 
as other cellular compartments such as tissue-resident myeloid cells may harbor persistent 
HIV after ART.85,86 However, the difficulty in isolating myeloid cells from tissue 
compartments limits the analysis of these cell types to in situ hybridization approaches (i.e., 
HIV-DNAscope and HIV-RNAscope) and non-human primates. Therefore, our current 
inability to account for the potential retention of persistent HIV in myeloid subsets after 
ART highlights a gap in our ability to monitor this compartment in clinical trial design. 
Finally, rapid autopsies are useful to obtain viable deep tissues from PWH on ART 
participating at the end of life studies, but they are likely not useful in interpreting change in 
reservoirs after an intervention as an autopsy provides a one-time measurement.87
Host surrogates of reservoir size
To gain insight into the host pressures that control HIV persistence, latency and reactivation, 
a comprehensive examination of host factors and cell subsets contributing to viral outgrowth 
ex vivo and rebound viruses in vivo after an ATI is needed. Regarding host factors, rebound 
HIV isolates after an ATI, but not those activated to by outgrowth ex vivo in a QVOA, are 
uniformly resistant to the antiviral activities of type 1 interferons (IFN-I). This observation 
indicates that tissue-specific innate responses limit the viruses that successfully reactivate 
from latency.88 Phenotypic analyses of QVOA and rebound isolates, including a comparison 
of their replicative fitness, cell tropism, glycosylation changes, and neutralization sensitivity 
can provide further insight into the host factors that maintain the latent HIV reservoir and 
may allow tracking the provenance of the rebounding virus.89 In addition to the phenotypic 
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analyses of QVOA and rebound, several studies have shown associations between host 
immune-related factors and HIV persistence during ART. Cell surface expression of negative 
immune checkpoints (PD-1, TIGIT, and LAG-3) correlates with levels of HIV DNA and 
RNA during ART.90–92 The expression of select anti-HIV host restriction factors are also 
associated with levels of cell-associated HIV RNA during ART.93 Levels of anti-HIV 
antibodies can reflect both the degree of HIV persistence and low-level viral replication.
94–96 While we have focused this perspective on virological measurements of persistent HIV 
reservoir, it is our view that concurrent measures of host factors associated with changes in 
viral reservoirs or rebound could be a critical component in understating the impact of 
potential interventions on the totality of the body’s HIV reservoirs during a cure-directed 
trial.
Analytical Treatment Interruptions (ATI)
The likelihood of rebound is thought to be a function of both the size of the inducible 
replication-competent reservoir and the strength of the immune responses. Clinical data have 
as yet failed to reveal a threshold of the number of the virus measured while ART-
suppressed by any laboratory viral assay below which rebound will not occur.34,97 The 
inability of viral measures alone to predict a lack of rebound may reflect the absence of 
taking into account host immune measures. With regards to viral measures alone, modeling 
studies suggest that a very large reduction in the replication-competent virus levels would be 
needed to significantly delay viral rebound in vivo.98 However, the limitation of modeling 
studies focused on changes of viral reservoir measures during ART is most evident with 
interventions designed to protect cells from infection, such as zinc finger nuclease induced 
cleavage of CCR5,99 or modulation of immune functions, such as chimeric antigen receptor 
(CAR) modified T-cells. These interventions would require an ATI to assess outcomes.
In addition, recent data using QVOA have revealed another potentially broader limitation of 
evaluating HIV within any one tissue compartment (i.e., peripheral blood). Specifically, 
QVOA HIV sequences induced from isolated CD4+ T cells from PBMC and expanded ex 
vivo differ, in some cases, from predominant HIV sequences detected in blood after ATI.
100–102 The explanation for this discordance remains under investigation but may reflect: 
inadequate sampling depth of the peripheral reservoir to detect rare cells that may cause 
rebound during ATI; distinct latent virus populations in the peripheral blood versus the 
tissues from which virus rebounds;103 differences between ex vivo stimulation in the 
presence of a uniform activation (e. g. mitogens or anti-CD3/28/cytokines) versus host 
factors driving in vivo reactivation and viral amplification; and the absence of immune 
selection pressure in static ex vivo cultures when compared to the dynamic innate, humoral, 
and cell-mediated pressure influencing viral rebound in vivo.
Importantly, the onset of rebound during an ATI may be subject to sampling bias of 
circulating virus alone without accounting for changes in viral persistence within mucosal 
tissue compartments that house the majority of the potential reservoir as demonstrated by a 
broad sampling of tissue sites for HIV viral RNA and DNA.17 These studies revealed that 
98% of the viral DNA and RNA is detected in the gut and lymph node. The inability of the 
field to accurately quantify changes in these tissue-resident reservoirs represents a major 
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obstacle to the clinical development of approaches to shrink the reservoir. With regards to 
host factors, innate (plasmacytoid dendritic cell) and adaptive variables have been noted to 
predict viral rebound.104–106 Furthermore, the glycosylation signatures of plasma antibodies 
and other glycoproteins on ART associate with time-to-viral-rebound and viral setpoints 
upon ART cessation.107 Modeling efforts to best integrate the contribution of viral and host 
surrogate measures to predict viral reservoir levels and viral rebound remain to be 
developed.
Because of its high information value, we endorse the continued use of closely monitored 
ATIs with defined safety-based criteria for re-starting ART in cure-directed studies.
101,108,109 Criteria on how to address ATIs in study design were addressed in a recent 
consensus conference.110 It is the position of the BEAT-HIV Collaboratory that only HIV 
cure-directed strategies with pre-existing evidence of a significant reduction in levels of HIV 
persistence in vivo or antiviral mechanism of action in animal models, should proceed to 
include an ATI in trial design in order to establish a definitive measure on the impact on HIV 
control and/or reservoir size.
Conclusions
We provide the BEAT-HIV Collaboratory view for prioritization of currently available viral 
measures in the design of HIV cure-directed clinical trials as follows (Figure 1):
For a 100 ml blood draw prioritize the IPDA or Q4PCR (pending validation of either assay), 
followed by cell-associated RNA, then an inducible p24 assay, to be followed by measuring 
levels of integrated HIV DNA.
For leukapheresis products first prioritize Q4PCR or IPDA, then cell-associated RNA, 
followed with inducible p24 assay, and then confirmatory assays using either QVOA p24 
SIMOA or QVOA cfRNA. We also support the TILDA when evaluating strategies aimed to 
stimulate or block HIV transcription. We further support the usage of the mVOA assay as a 
confirmatory test if there is a lack of replication-competent virus or HIV DNA/RNA and an 
absence of an ATI in the trial design. If resources are available and the strategy is expected 
to result in a subset of controllers, we support the inclusion of full-genome sequencing, 
including integration site and orientation analysis in order to investigate the qualitative 
potential for HIV reactivation by residual reservoirs that persists after viral control.
For tissues, prioritize the IPDA or Q4PCR, then DNA/RNAscope in situ hybridization, 
followed by both cell-associated RNA and inducible p24 assay with added measures for 
levels of HIV DNA, where feasible. Importantly, HIV reservoir reduction determined by any 
of the aforementioned assays does not indicate potential durable viral control or eradication 
without the inclusion of an ATI in trial design as no viral measurement has yet predicted a 
lack of viral rebound after discontinuation of ART.
It is also important to note that “one size does not fit all” as the interpretation of viral 
measures (latent or active reservoirs) on ART and how they are to be prioritized and 
analyzed during HIV cure-related clinical trials may differ relative to the mechanism 
anticipated for viral clearance; emerging methods for added measures of the HIV reservoirs 
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using single-cell technologies; and resources available and sample availability. In 
conclusion, study plans need to carefully weigh the ultimate mechanistic insight and impact 
of performing any selected assay relative to the value of banking samples for future 
interrogation.
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The BEyond Anti-retroviral Therapy Martin Delaney Collaboratory to Cure HIV-1 
Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) is a consortium of 
HIV researchers from leading academic research institutions working with government, 
nonprofit organizations, and industry partners. BEAT-HIV Collaboratory objectives are to 
advance basic cure-directed research and to conduct HIV cure-directed clinical trials 
using immune-based therapies. The BEAT-HIV Collaboratory is supported by NIAID, 
NIMH, NINDS, and NIDA, and The Philadelphia Foundation. For added information and 
full membership go to beat-hiv.org.
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collective term for cells infected with replication-competent HIV in blood and various 
anatomical sites that persist despite long-term antiretroviral therapy and cause viral 
rebound upon therapy interruption.
HIV latent reservoir:
the major component of the HIV reservoir and defined as quiescent cells carrying an 
integrated copy of the viral genome that does not express viral transcripts or proteins.
HIV active reservoir:
A minor population of transcriptionally-active cells, producing HIV RNA/proteins and 
possibly virions, that can be detected in people living with HIV despite long-term 
therapy.
HIV proviral/provirus:
viral DNA integrated into the infected cell genome.
Near full-length HIV proviral sequencing:
Sequencing of almost the entire integrated viral genome within the infected cell genome.
Intact HIV proviruses or genomes:
HIV proviral sequence that does not contain massive deletions or mutations that can 
render them defective, and therefore these intact proviruses have a high potential for 
replication competency.
Defective HIV provirus:
HIV provirus that is inserted into the genome of an infected cell yet harbors mutations 
and/or deletions rendering them defective and unable to replicate
Inducible HIV provirus:
HIV provirus that able to be induced to produce viral RNA, viral protein, and/or virions.
Transcriptionally-competent HIV provirus:
HIV provirus that can produce viral RNA transcripts.
Translationally-competent HIV provirus:
HIV provirus that can produce viral proteins (such as p24).
Replication-competent HIV provirus:
HIV provirus that can produce and release virions able to replicate, resulting in 
productive infection and viral amplification.
Clonal HIV proviral expansion:
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Expansion of a specific HIV provirus due to the proliferation of an HIV-infected cell 
carrying this provirus.
Outgrowth assays:
Methods to induce expression/replication of HIV ex vivo using cells obtained from an 
individual living with HIV (typically ART-suppressed individual).
Analytical Therapy Interruption (ATI):
cessation of antiretroviral therapy followed by monitoring viral rebound.
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The collective view of the BEAT-HIV Collaboratory on the priority for measuring HIV 
reservoir size, in blood and tissues, during HIV cure-related clinical trials.
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